Paul Reider
Corporate Officer/Principal at COHERUS BIOSCIENCES, INC.
Net worth: 194 252 $ as of 2024-03-30
Profile
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-19 | 81,277 ( 0.07% ) | 194 252 $ | 2024-03-30 |
Paul Reider active positions
| Companies | Position | Start |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 2020-12-31 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Former positions of Paul Reider
| Companies | Position | End |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 2020-12-31 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Training of Paul Reider
| Bowling Green State University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
- Stock Market
- Insiders
- Paul Reider
